Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to $1.7 million.

  • Ensysce Biosciences' Cash & Equivalents fell 5971.64% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 5971.64%. This contributed to the annual value of $3.5 million for FY2024, which is 21168.25% up from last year.
  • Per Ensysce Biosciences' latest filing, its Cash & Equivalents stood at $1.7 million for Q3 2025, which was down 5971.64% from $2.2 million recorded in Q2 2025.
  • Ensysce Biosciences' 5-year Cash & Equivalents high stood at $12.3 million for Q4 2021, and its period low was $1.0 million during Q2 2024.
  • For the 5-year period, Ensysce Biosciences' Cash & Equivalents averaged around $4.7 million, with its median value being $3.3 million (2022).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 1269756.23% in 2021, then crashed by 8322.74% in 2023.
  • Quarter analysis of 5 years shows Ensysce Biosciences' Cash & Equivalents stood at $12.3 million in 2021, then plummeted by 74.34% to $3.1 million in 2022, then plummeted by 64.3% to $1.1 million in 2023, then soared by 211.68% to $3.5 million in 2024, then plummeted by 52.22% to $1.7 million in 2025.
  • Its Cash & Equivalents stands at $1.7 million for Q3 2025, versus $2.2 million for Q2 2025 and $3.1 million for Q1 2025.